The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT
Official Title: Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Hematologic Malignancies
Study ID: NCT05084027
Brief Summary: venetoclax combining with fludarabine and melphalan as conditioning regimen prior to allogeneic hematopoietic stem cell transplantation for older patients with hematologic malignancies
Detailed Description: It was a phase Ⅱ clinical trial of new designed reduced-intensity conditioning regimen for older patients accepting allogeneic hematopoietic stem cell transplantation treatment. The regimen consisted of venetoclax combining with fludarabine and melphalan.
Minimum Age: 50 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
The first Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
First Affiliated Hospital of Zhejiang Chinese Medicine University, Hangzhou, Zhejiang, China
Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China
Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, , China
Zhejiang Provincial People's Hospital, Hangzhou, , China
Ningbo Hospital of Zhejiang University, Ningbo, , China
The Affiliated People's Hospital of Ningbo University, Ningbo, , China
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, , China
Name: Yi Luo, M.D.
Affiliation: First Affilaated Hospital of Medical School of Zhejiang University
Role: PRINCIPAL_INVESTIGATOR